Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

A biotech developing what it says is an “opioid-like” pain reliever released Phase 3 data Wednesday morning claiming the drug ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

ArriVent BioPharma, led by Bing Yao, licenses ADC MRG007 from Lepu Biopharma for $47M upfront, adding the drug to a portfolio ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

Chinese biotechs Bao Pharma & Biokin file for Hong Kong listings, Disc Medicine plans $200M offering, Rivus adds $57M to Series B & Crown Labs raises Revance bid to $3.65/share ...

The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...